Abstract
Transcatheter aortic valve implantation (TAVI) is expanding to younger patients and the management of valve failure is a growing clinical problem. The transcatheter heart valve (THV) of choice for redo - TAVI is a complex decision and first reports have examined the use of the Sapien 3TM THV (Edwards Lifesciences; Irvine, CA, USA) in failed EvolutTM (Medtronic, Minneapolis, MN, USA) THV. However, several different technical approaches may be worth consideration, and the subject remains a matter of debate. A 73-year old female with previous coronary artery by-pass grafting (CABG), percutaneous coronary intervention (PCI) and TAVI with a 26 mm EvolutTM R THV presented with signs of heart failure. The clinical investigation revealed a severe restenosis of the THV valve and a stenosis of the left coronary main stem. The patient was successfully treated with PCI of the left main and, during the same procedure, underwent implantation of a 25 mm NavitorTM THV (Abbott; Chicago, Il, USA). This case presentation aims to illustrate the rationale of and necessary conditions for performing a TAVI-in-TAVI procedure with NavitorTM THV in a failed EvolutTM THV which, to our best knowledge, constitutes a novel approach to redo - TAVI.

This publication has 10 references indexed in Scilit: